Results 31 to 40 of about 14,264 (186)
Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy [PDF]
Vojnosanitetski Pregled, 2007 Background/Aim. Insulin glargine is a long-acting insulin analog that mimics normal basal insulin secretion without pronounced peaks. The aim of this study was to compare insulin glargine with isophane insulin (NPH insulin) for basal insulin supply in ...
Pešić Milica +5 more
doaj +1 more source
Effects of insulin and analogues on carcinogen-induced mammary tumours in high-fat-fed rats
Endocrine Connections, 2018 It is not fully clarified whether insulin glargine, an analogue with a high affinity for insulin-like growth factor-1 receptor (IGF-1R), increases the risk for cancers that abundantly express IGF-1R such as breast cancer or some types of breast cancer ...
Yusaku Mori +8 more
doaj +1 more source
In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. [PDF]
PLoS ONE, 2010 BACKGROUND: Insulin glargine (Lantus) is a long-acting basal insulin analog that demonstrates effective day-long glycemic control and a lower incidence of hypoglycemia than NPH insulin.
Mark R Sommerfeld +6 more
doaj +1 more source
Mìžnarodnij Endokrinologìčnij Žurnal, 2016 This review examines the new formulation of insulin glargine (recombinant) in the form of injections 300 U/ml (Gla‑300, Toujeo®). Gla‑300 is a next generation basal insulin with a novel formulation of insulin glargin delivering the same amount of insulin,
V.V. Poltorak
doaj +1 more source
Basal insulin titration algorithms in patients with type 2 diabetes: the simplest is the best (?)
Mìžnarodnij Endokrinologìčnij Žurnal, 2023 Basal insulin is the first and main component of insulin therapy in patients with type 2 diabetes mellitus (T2DM). Based on the shortcomings of human NPH insulin and the advantages provided by long-acting basal insulin analogues, they are recommended ...
V.I. Katerenchuk
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang +5 more
wiley +1 more source
Clinical Diabetology, 2021 Introduction. Insulin glargine 100 U/ml (Gla-100) is a long-lasting basal insulin analog injected once daily. This real-life study aimed to evaluate the efficacy and safety of Gla-100 in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM ...
Grzegorz Jan Dzida, Tomasz Szczepanik
doaj +1 more source
, 2009 A few months ago, a hot spot emerged in the area of diabetes and cancer epidemiology. Hemkens et al., from the Institute for Quality and Efficiency in Health Care, published in Diabetologia a report of an observational cohort study based on a large ...
Meigs, James B +1 more
core +1 more source
Modern basal insulin analogs: An incomplete story
Indian Journal of Endocrinology and Metabolism, 2014 The currently available basal insulin does not completely mimic the endogenous insulin secretion. This has continued to promote the search for ideal basal insulin.
Awadhesh Kumar Singh +1 more
doaj +1 more source
Considerations for the Integration of Clinical Trials and Real‐World Data
Clinical Pharmacology &Therapeutics, EarlyView.As clinical decision‐making increasingly moves toward individualized and context‐specific treatment recommendations, reliance on any single evidence source, randomized or observational, may be insufficient. Principled integration of randomized controlled trials and real‐world data, grounded in explicit causal frameworks, offers a path toward evidence ...
Sky Qiu +19 more
wiley +1 more source